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Abstract Coronary artery disease is a growing problem
worldwide. Early treatment with stabilizing drugs and
revascularization by percutaneous coronary intervention or
by-pass surgery has reduced the mortality significantly, but
it is still the most common cause of death and a major cause
of hospital admissions in industrialized countries. Treat-
ment with stem cells with the potential to regenerate the
damaged myocardium is a relatively new approach.
However, the results from clinical studies on stem cell
therapy for cardiac regeneration in patients with acute or
chronic ischemic heart disease have been inconsistent.
Some of the discrepancy could be due differences in study
designs or patient selection. The review will based on
conducted clinical stem cell trials try to elucidate how to
predict and personalize this new treatment approach.
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Introduction
Despite advances in drug therapy and percutaneous
interventions, ischemic heart disease remains a major cause
of mortality and morbidity in industrialized countries.
Morbidity in survivors of the acute coronary syndrome is
related to myocardial remodeling and progressive heart
failure. It has, therefore, been a challenge in clinical
research to find new treatment modalities that aim to
reduce and repair the myocardial damage and improve
blood supply to the myocardium in the ischemic heart.
Regenerative medicine with vascular growth factor and
stem cell therapy have within the last decennium had great
interest and have been tested in clinical trials in patients
with ischemic heart disease [1]. The aim is to induce
growth of new blood vessels or replacement of damaged
myocardial cells either directly by transdifferentiation of
stem cells or by a paracrine effect of cytokines secreted
from the stem cells.
Within cardiology most focus has been on bone marrow
derived hematopoietic stem cells, which have the potential
to differentiate into endothelial cells and create new blood
vessels and hereby be involved in myocardial vasculo-
genesis. Recently, several clinical safety and efficacy
studies with mononuclear cell solutions (MNC) and
selected endothelial progenitor cells (EPC) from the bone
marrow have been conducted in patients with acute
myocardial infarction (MI), chronic ischemic heart disease
(CIHD) or ischemic heart failure (IHF). However, the
results have been conflicting. Some but not all studies
suggested a beneficial effect on myocardial function and on
symptoms in acute and chronic myocardial ischemia [2–5].
These conflicting results have changed focus towards the
use of a more specific stem cell line. Some groups have
focused on the multi-potent mesenchymal stromal cell
(MSC) from the bone marrow or adipose derived stem cell
(ADSC), which easily can be isolated from the bone
marrow and abdominal adipose tissue, in vitro culture
expanded, and stimulated to differentiate into different cell
lines as endothelial, cardiac or other cell types [6–8].
The aim of this review is to discuss current issues on
regenerative stem cell therapy in patients with ischemic
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heart disease with focus on conducted clinical trials. With
focus on predictive and personalized patient treatment the
patient selection, stem cell type, cell source, delivery
methods, stem cell mechanisms will be considered.
Which stem cells are available for clinical treatment
Stem cells are self-replicating and have the capacity to
differentiate into at least one highly terminally differentiat-
ed specialized cell type [9]. Stem cells can be classified into
three categories with different potency, which specifies
their differentiation potential: 1. embryonic stem cells
(ESC), 2. adult stem cells, and 3. induced pluripotent stem
cells (iPS cells). Embryonic stem cells are derived from the
inner cell mass of the blastocyte stage of the developing
embryo. Adult stem cells are present in every tissue of the
human body and are able to differentiate into those tissues.
Most stem cells in clinical studies, whether it has been
MNCs or MSCs, have been harvested from the bone
marrow. However, MNCs and MSCs can also be harvested
from peripheral blood [10], umbilical cord blood [11] and
from adipose tissue [12]. In fact MSCs may reside in
virtually all post-natal organs and tissues [13]. Finally
through transcriptional reprogramming, somatic cells such
as fibroblasts can be converted into iPS cells that resemble
embryonic stem cells [14].
Bone marrow derived mononuclear cells
Bone marrow is the most frequent source of cells used in
clinical cardiac regeneration, because they are the most
easily accessible source of autologous cells for use in
reparative transplantation. MNCs can easily be harvested
from bone marrow aspirate and selected sub-fractions, as
EPCs, can be isolated using markers on the cell surface.
The use of the MNCs have the advantage of minimizing
extensive in vitro manipulations compared with isolation
and expansion of selected populations of cells. The
potential disadvantage of using MNCs, which is a mixture
of different cell types, is that the percentage of stem cells
that are therapeutically useful may potentially be small.
However, it is still debatable whether the potential clinical
effect is caused by the stem cells or the cytokines secreted
from the MNCs, since only 2% of the injected cells are
stem cells [5].
Bone marrow derived mesenchymal stromal cells
MSCs are an easily obtainable stem cell source, which can
be expanded in culture systems and differentiated into
several different cell types in vitro under proper stimulation.
For regenerative medicine MSCs have mostly been isolated
from the low-density MNC population in the bone marrow,
based on their selective adherence to plastic surfaces and by
this method separated from the hematopoietic cells, which
do not adhere to plastic surfaces [15]. The MSC population
is rare in the bonemarrow, accounting for only about 0.01% of
bone marrow mononuclear cells [6]. Hence, the MSCs
require substantial culture expansion for weeks prior to most
experimental applications [16–18] (Fig. 1). MSCs can
differentiate into endothelial progenitor cells by stimulating
with vascular endothelial growth factor (VEGF) [18, 19] and
into cardiomyocytes by a cocktail of growth factors [20],
chemicals [21] or by microenvironment in vivo [22].
Adipose tissue derived stem cells
Due to the small number of MSCs in the bone marrow, an
additional source of cells with the aforementioned multi-
lineage properties is desirable [23]. An interesting alterna-
tive cell source is the ADSCs from adipose tissue. These
ADSCs appear to have similar multi-lineage potential as
bone marrow MSCs [24–27]. ADSCs can be retrieved via
liposuction, and processed by enzymatic digestion, centrif-
ugal enrichment and filtration methods [28]. The final cell
solution adipose derived cells (ADC) contains an abundant
population of ADSCs, approximately 100–300 fold more
MSC-like cells than that found in bone marrow. Therefore,
the following cultivation period to expand the number of
ADSC can be reduced. For cell based therapies, the large
number of ADSCs that can be harvested within a single
surgical procedure could be an advantageous approach that
reduced lengthy and costly in vitro culturing steps [29].
Induced pluripotent stem cells
An interesting new alternative cell type is iPS cells. These
are adult somatic cells reprogrammed into pluripotent stem
cells, by introducing pluripotency-associated transcription
factors. The iPS cells acquire properties similar to those of
ESCs [14, 30]. This technology could potentially eliminate
two important problems associated with ESCs: immune
rejection after transplantation and the ethical concerns
regarding the use of human embryos. But there are also
other problems to be addressed for the iPS cells. One of
these is teratoma formation identical to what is seen with
ESCs [30, 31]. Even a small number of undifferentiated
cells can result in the formation of teratomas. One way to
solve this problem may be to induce differentiation of the
iPS cells into the required cell types before treatment,
leaving the few undifferentiated cells behind [32].
Current iPS cell technology depends largely on delivery of
the reprogramming factors by use of retroviral or lentiviral
vectors, which may lead to activation of oncogenes [33]. To
ensure a safe clinical application of iPS-derived cells,
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developing non-viral methods for generating iPS cells, where
inserted transgenes can be subsequently removed, is manda-
tory. The novel transposon-based and protein transduction
methods allow for such a strategy [33, 34]. However, before
iPS cells are ready for human clinical trials many open
questions remain to be solved.
Optimal stem cells delivery to the heart: advantages
and disadvantages
The optimal method for delivery of stem cell treatment to
the damaged heart is still unclear. Most studies have used
intravenous (IV), intracoronary (IC) or intramyocardial
(IM) injection. For IC delivery most studies used a stop-
flow technique trough an over-the-wire balloon catheter
positioned within the segment containing the stent. To
allow for adhesion and potential transmigration of the
infused cells through the endothelium, the balloon normally
is inflated to completely block blood flow for 3 min while
suspension of cells is infused distally to the occluding
balloon [2–5].
Most studies using IM injection for delivery have used
the NOGA XP system for mapping of the left ventricle and
to guide the injections usually in the border area between
normal and dead endocardial tissue or in the viable
ischemic myocardium [35–37] (Fig. 2). Although IM
injection of skeletal myoblasts have been demonstrated to
have a pro-arrhythmogenic effect [37–39], IM injection of
bone marrow derived stem cells and angiogenic genes have
been reported to be safe without arrhythmias or death [5,
35–37, 41, 42].
A study on pigs with MI compared IV, IC and IM
delivery of MSCs [43]. IC and IM delivery showed increased
engraftment in the infracted heart compared to IV delivery,
and IM injection of MSCs was found to be more efficient than
IC delivery. A side effect of IC delivery was a decreased blood
flow distal to the infusion site. The same side effect was seen
in another study in dogs, where IC delivery of MSCs caused
micro-infarction, probably due to microvascular obstruction
caused by the rather large cell size of MSCs [44]. In
opposition, a few clinical human studies have injected MSCs
IC without complications [45–48].
Stem cell regenerative potential: lessons from clinical
trials with mononuclear cells
Clinical stem cell therapy is still in its early experimental
stages. Most clinical data have come from small non-
randomized and a few randomized, controlled trials
conducted in patients with acute MI, CIHD and IHF with
injection of stem cells either IC, IV, IM or during coronary
artery by-pass grafting.
Acute myocardial infarction
Initial open-label trials of autologous MNCs documented
safety and feasibility in patients with MI [49–52]. Then,
larger independent randomized studies using autologous
MNCs have been reported in MI patients [2–4, 53–61]
(Table 1).
MNCs were in an open non-randomized study injected
IC in 10 MI patients demonstrating increased LVEF,
enhanced LV systolic function and reduced scar tissue after
3 months [50]. The same group recently reported 5-year
data on an open non-randomized study on 62 IC treated
patients with MI (the BALANCE study) [57]. Results
supported the initial findings with improve LVEF and
reduced scar tissue, in addition with an improved exercise
capacity and reduced mortality in a 5-year follow-up
period. The open randomized study on IC injection of
MNCs in 30 STEMI patients (the BOOST trial) also
showed increased LVEF and enhanced systolic function
after 6 months [51], but after 18 months the difference in
LVEF was no longer significant [58], suggesting that stem
cell treatment merely accelerated LVEF recovery. The
TOPCARE-AMI trial, another open randomized study on
Week 1 Week 3 Week 5 Week 2
Fig. 1 Cultivation of mesenchymal stromal cells for clinical treat-
ment. Collagen staining. The cells needs several weeks of proliferation
to reach a sufficient number for clinical treatment. The cells are
becoming more and more confluent during cultivation and when they
are approximately 80–90% confluent (week 5) they are harvested for
treatment or for the next expansion passage
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IC injection of either MNCs or circulating progenitor cells
(CPC) in STEMI patients, showed improved LVEF and
wall motion after 4 months (20 patients) [49] and also after
1 year (62 patients) [59]. There was no difference in effect
between cell types. The REPAIR-AMI trial, a double
blinded placebo controlled study on IC injected MNCs in
204 STEMI patients, showed improved LVEF and reduced
mortality and re-hospitalization after 4 months [4] and the
results were also stable after 1 year [60]. In opposition to
these results, several trials have not been able to detect any
Fig. 2 NOGA mapping of left
ventricle with intramyocardial
injections of mesenchymal
stromal cells (brown spots). A
mapping catheter is introduced
percutaneously from the groin
into the left ventricle across the
aortic valve. The catheter is then
used for creating a tree-
dimensional image of the left
ventricle and for injection of
stem cells into the ventricular
myocardium (outlined with the
white line)
Table 1 Randomized controlled trials with bone marrow mononuclar cells in patients with acute myocardial infarction
N Treated/
controls











9/11 MNC/CPC 245x106/10106 Day 4 i.c. ↑(4 months) ↑Viability
REPAIR-AMI 2006 [60] 101/103 MNC 240×106 Day 3–6 i.c. ↑(4 months) NA
Leuven-AMI 2009 [2] 33/34 MNC 170×106 Day 1 i.c. ↔(4 months) ↓
ASTAMI 2006 [3] 50/50 MNC 87×106 Day 6 i.c. ↔(6 months) ↔
FINCELL 2008 [54] 40/40 MNC 360×106 Day 3 i.c. ↑(6 months) NA




Day 3–12 i.c. ↔ between groups
(6 months)
NA
HEBE 2008 [53] 26/0 MNC 246×106 Day 3–8 i.c. ↑ (4 months) ↓
BALANCE 2009 [57] 62/62 MNC 61×106 Day 7 i.c. ↑ (43 months) ↓






i.c. ↑ (9–12 months)
i.c. 1300×106
vs 1300×106
MNC Bone marrow mononuclear cells, CPC circulating progenitor cells, i.c. intracoronary, NA Not available
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effect of MNCs treatment on LV function after MI. The
ASTAMI trial could not detect any improvement in LV
function measured by magnetic resonance imaging (MRI)
and SPECT in a randomized trial with IC injection of
MNCs in 100 patients with MI [3]. Moreover, the Leuven
MI trial with treated 67 patients with MI with either IC
MNCs or placebo without any detectable effect on LV
recovery measured by MRI [2]. However, the reduction in
infarct size was greater in MNCs treated compared to
placebo. In the HEBE trial, 200 patients with MI were
treated with either MNC from bone marrow; MNC
isolated form peripheral blood or treated with standard
therapy [53]. The study could not demonstrate any
improvements in global or regional LV systolic function
assessed with MRI.
These conflicting clinical results have changed the focus
towards the use of a more specific stem cell line or
progenitor cell from the bone marrow to improve the
outcome of the treatment. In the REGENT trial, Tendera et
al. addressed this important issue by comparing IC infusion
of unselected mononuclear cells with infusion of cells
positive for surface markers CD34 and CXCR4 in patients
with MI [56]. The REGENT trial was a multicenter study
randomizing two hundred patients into IC infusion of
bone marrow-derived mononuclear cells (n=80), CD34+
CXCR4+ cells (n=80), or to a control group without cell
treatment (n=40). The study demonstrated no significant
attenuation of left ventricular remodeling after cell therapy
with absolute change in LVEF measured with MRI.
However, this result should be interpreted with caution.
The authors did observe an absolute increase of 3% in the
patients treated with either of the two cell solutions
compared to no change in the control group. This
difference did not reach statistical significance but is
comparable to the effect of cell therapy found in the larger
randomized and blinded REPAIR-AMI trial (2.5%, p=
0.01) and in the meta-analysis [60, 61]. It could thus be
argued that the REGENT trial is bias by a statistical type 1
error and also affected by a selection bias due to the non-
blinded design. Gyöngyösi et al. tested the effect of
repeated injections of MNCs. Patients with left ventricular
ejection fraction less than 45% after MI were randomly
assigned stem cell delivery via IM and IC infusion 3–
6 weeks or 3–4 months after MI [54]. This combined
MNC delivery treatment induced a moderate but signifi-
cant improvement in myocardial infarct size and left
ventricular function.
A meta-analysis from 2008 including 13 randomized
controlled trials of bone marrow stem cell transplantation
following MI reported a 2.99% improvement in LVEF
compared to controls (p=0.0007) [61]. Whether these
results still stands after inclusion of recent negative trials
has to be clarified in new updated meta-analysis.
Ischemic heart failure
Intramyocardial injection of skeletal myoblasts during by-
pass surgery has been tested in 94 patients with ischemic
heart failure (IHF) in the randomized placebo-controlled
MAGIC trial [62] (Table 2). At the 6 months follow-up,
there was no difference in regional or global LV function
between the two groups. There was a trend towards more
arrhythmias in the myoblast treated patients, confirming the
safety concern that had been raised in earlier, non-
randomized trials. Perin et al. was the first group to inject
MNCs directly IM using the percutaneous transendocardial
method in 14 patients with IHF [5]. The method was safe
and there was an improvement in LVEF and myocardial
perfusion for up to 12 months compared to a control group
(n=7). Improved LVEF and NYHA class was also
demonstrated in 15 patients with IHF after IM injection of
MNCs [63]. The TOPCARE-CHD trial randomized 75
patients to either IC delivered MNCs or circulating
progenitor cells (CPC) [64]. There was an improvement in
LVEF, assessed with contrast angiography, with the MNC
but not with the CPC treatment. Diederichsen et al. injected
MNCs IC twice within a 4 months period in 32 patients
with IHF without any effect on LVEF, but with an
improvement in NYHA class [65]. In a recent trial Strauer
et al. injected MNCs IC in 191 patients with IHF and
follow the treated and a non-randomized control group for
up to 5 years [66]. The study demonstrated improvement in
LVEF, exercise capacity, oxygen uptake and long-term
mortality in the entire follow-up period.
The more selected MNC subpopulation CD133+ has also
been used in clinical trials. Ahmadi H et al., injected
CD133+ MNCs directly into the infracted myocardium in18
patients undergoing CABG and compared with patients
which went through CABG alone [67]. They demonstrated
a significant improvement of regional wall motion of
akinetic/dyskinetic segments and perfusion of infracted
areas in patients receiving local transplantation of CD133+
cells in conjunction with CABG surgery, compared with a
control group treated with CABD alone.
Chronic ischemic heart disease
Several small non-randomized and un-controlled trials with
autologous MNCs have been conducted in patients with
chronic ischemic heart disease (CIHD) [68–78] (Table 3).
There was an improvement in LVEF, exercise capacity and
symptoms in 20 patients with ICHD after IM injection of
MNCs [69]. The same group demonstrated a few years later
in 24 patients with CIHD that MNCs improved diastolic
function 3 months after treatment [75]. Kang et al.
demonstrated improved LVEF after IC injection of MNCs
in opened total coronary occlusion [70]. Intramyocardial
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injection of MNCs has been used in 27 patients with
advanced CIHD and followed for a year [40]. The study
showed improvement of symptoms (Canadian Cardiovas-
cular Society angina class (CCS)), exercise capacity and
stress induced ischemic score. These data was supported by
in the PROTECT-CAD trial, where IC injection of MNCs
in 28 patients with CIHD improved NYHA class, exercise
time and LVEF [76]. In a randomized, double-blind,
placebo-controlled trial van Ramshorst et al. treated 50
patients with IM injections of MNCs or saline [77]. The
study demonstrated improved myocardial perfusion, LVEF,
exercise capacity and CCS class.
Losordo et al. injected IM increasing number of MNC
subpopulation CD34+ cells in patients with CIHD [78]. The
patients improved in angina, exercise capacity and anti-
angina medication. The disadvantage of the use of the
MNC subpopulations CD133+ and CD34+ for clinical use
is that they are usually only available in small and potential
inadequate quantities from a patient, because the cells are
very rare in bone marrow.
The mesenchymal stromal cell: a more homogenous cell
line for regeneration?
Only a few small phase I/II safety and efficacy clinical
studies on the therapeutic potency of human in vitro
culture-expanded autologous MSCs in a less than 150
Table 2 Clinical trials with stem cells in patients with chronic ischemic heart failure
N treated/
controls
Cell type Cell number Administration Treatment
effect LVEF
Symptoms
Perin et al. 2004 [5] 11/9 MNC NA i.c. ↔(12 months) NYHA↓, exercise↑
Assmus et al.
2006 [64]





15/0 MNC 94×106 i.c. ↑(3 months) Exercise↑
Ahmadi et al.
2007 [67]




32/0 MNC (baseline) vs
MNC (4 months)
650×106/890×106 i.c. ↔(12 months) NYHA↓
Menarsche et al.
2008 [62]
33/34/30 SKM 400×106/800× 106 i.m. ↔(6 months) NA
Strauer et al.
2010 [66]
191/200 MNC 66×106 i.c. ↑(60 months) Exercise↑, mortality↓
MNC Bone marrow mononuclear cells, SKM skeletal myoblasts, i.c. intracoronary, i.m. intramyocardial, LVEF left ventricular ejection fraction,
NYHA New York Heart Association class, NA not available
Table 3 Clinical trials with bone marrow mononuclear cells in patients with chronic ischemic heart disease
N treated/
controls
Cell type Cell number Administration Treatment
effect LVEF
Symptoms
Erbs et al. 2005 [68] 13/13 CPC 69×106 i.c. ↑ (3 months) NA
Fuchs et al. 2006 [41] 27/0 MNC 28×106 i.c. ↔(3 and 12 months) CCS↓, exercise↑
Beeres et al. 2006 [69] 20/0 MNC 30–100×106 i.c. ↑(6 months) CCS↓, exercise↑
Hendrikx 2006 [71] 10/10 CABG+/−MNC 60×106 i.m. ↔(4 months) NA
Kang et al. 2006 [70] 25/25 vs 16/16 MNC 1400×106 i.c. MI↑/CIHD↔
(6 months)
NA
Tse et al. 2007 [73] 9/10/9 MNC 17×106, 42×106 i.m. ↑(6 months) NYHA↓, exercise↑
Losordo et al. 2007 [78] 6/6/6/6 CD34+ 0.05×106, 0.1×106
or 0.5×106
i.m. NA(6 months) CCS↓, exercise↑,
NTG↓
Beeres et al. 2008 [75] 24/0 MNC 85×106 i.c. ↔(3 months) Diastolic function↑
Van Ramshorst et al.
2009 [77]
25/25 MNC 98×106 i.m. ↑(3 months) CCS↓, perfusion↑
MNC Bone marrow mononuclear cells, CPC circulating progenitor cells, i.c. intracoronary, i.m. intramyocardial, LVEF left ventricular ejection
fraction, CCS Canadian Cardiovascular Society angina class, NYHA New York Heart Association class; NTG Nitroglycerin consumption, NA not
available
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patients with CIHD, MI or IHF have been published [45–
48, 79] (Table 4).
In an open study with IC administered MSCs in 11 MI
patients, the treatment was safe and showed improved wall
motion index and non-viable segments [45]. The same
group also investigated if there were any arrhythmogenic
side-effects of MSCs treatment on five patients with an ICD
units. Within 16–36 months follow up period there was no
episodes of either sustained or non-sustained ventricular
tachy-arrhythmia [46]. An open randomized study on IC
delivered MSCs in 34 MI patients was safe and showed
improved LV function after 6 months [47]. In another
randomized study patients with severe heart failure were
treated with MSCs IC and followed for a year [48]. The
results showed improved LVEF, exercise capacity and
NYHA class.
Safety of IV treatment with allogeneic bone marrow
derived MSCs in patients with acute MI treated initially
with balloon angioplasty was recently investigated in a
randomized double-blind placebo-controlled dose-
escalating study [80]. The study demonstrated that the
treatment was safe with identical adverse event rates
between MSCs and placebo treated patients. However,
MSCs treated patients had reduced ventricular tachycardia
episodes, global symptom score and LVEF.
Kastrup et al. (unpublished data) has investigation the
feasibility, safety and efficacy of IM injections of autolo-
gous MSCs derived endothelial precursor cell in patients
with stable CIHD and refractory angina. The study
demonstrated that it was possible and safe to culture
expand MSCs and stimulate the cells with VEGF-A165
towards endothelial precursor cells and then to inject the
cells directly into the ischemic myocardium of the patients.
In addition, there was a graduate improvement in the
patient’s symptoms, exercise capacity, CCS class, angina
attacks, nitroglycerine consumption and LVEF from base-
line to 3 and 6 months follow-up.
Conclusions
Most of the clinical stem cell trials have used a pragmatic
design with transplantation of a heterogeneous population
of bone marrow-derived mononuclear cells—giving little
information regarding the effective cell type. Some minor
studies have tried to evaluate the efficacy of more specific
cell lines as CD34+, CD133+ or MSCs. However, the
studies differed in design, patient numbers, cell prepara-
tion methods, timing of cell transplantation after percuta-
neous coronary intervention, and imaging modalities to
evaluate the end-points. Some but not all studies
suggested a beneficial effect on myocardial function and
on symptoms. The reasons for these divergent findings are
still unclear.
Mononuclear cell—what have we learned?
The REPAIR-AMI [60] and the ASTAMI [3] trials with
MNCs treatment of patients with MI demonstrated com-
pletely opposite clinical outcome. Therefore, a comparison
of the isolated cell infusate used in two studies was
conducted by the REPAIR-AMI group. These results
revealed important differences in bone marrow cell func-
tionality, depending on laboratory procedure used [81]. The
authors discuss whether lack of beneficial effect on the
global left ventricular function could be related to impaired
cell quality or insufficient cell number. However, Egeland
and Brinchmann from the ASTAMI group did not agree
about the cell quality question in ASTAMI study [82].
Presently this topic is still for discussion.
Table 4 Clinical studies with mesenchymal stromal cell (MSC) treatment of patients with ischemic heart disease
Patients N Treated/
controls
Study design Cell type Cell number Administration Treatment effect
Chen et al. 2004 [47] MI 34/35 I MSC autologous 6×1010 i.c. LVEF↑
Chen et al. 2006 [48] MI 22/62 I MSC autologous 5×106 i.c. LVEF↑ exercise↑
Katritsis et al. 2005 [45] MI 11/11 II MSC autologous i.c. LV wall motion↑
Katritsis et al. 2007 [46] MI 5/0 II MSC autologous i.c. No arythmia
Mohyeddin-Bonab
et al. 2007 [79]
8/8 II MSC autologous i.m. LVEF↑




Kastrup et al. 2010
(unpublished)
CIHD 31/0 I MSC autologous 22×106 i.m. Exercise↑ LVEF↑ CCS↓
NTG↓ (6 months)
MI acute myocardial infarction, CIHD chronic ischemic heart disease, I open randomized study, II open non-randomized study, III randomized
double-blind placebo controlled study, i.c. intracoronary, i.m. intramyocardial, i.v. intravenous, LVEF left ventricular ejection fraction, CCS
Canadian Cardiovascular Society angina class, NTG Nitroglycerin consumption
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Different cell types have been used in the different trials.
Therefore, it has been discussed whether different cell types
may give different clinical outcome. This question was
addressed in the REGENT trial that compared the efficacy
of IC injection of MNCs and CD34+CXCR+ cells in
patients with MI [56]. The improvements in LVEF were
virtually identical comparing these two cell populations.
This may give important novel cell mechanistic insight. The
selected cells CD34+CXCR+ were eluded from 100-120 mL
bone marrow whereas the unselected cells MNCs (also
containing CD34+CXCR+) were eluted from 50–70 mL of
bone marrow. Thus if the elution processes were identically
effective then patients in the “selected” group were infused
with approximately 2 times the number of CD34+CXCR+
cells compared to the amount contained in the MNCs
infused in the “unselected” patient group. The interpretation
of this result is difficult; a similar improvement with
unselected and selected cells argue in favor for a role of
the selected CD34+CXCR+ cells in the mechanism behind
the effect. However, if this effect is not dose dependent it
would argue for a more indirect paracrine effect, e.g. via
enhanced capillary growth, prevention of host cell death or
even stimulation of resident stem cells. It is however,
remarkable that enhanced mobilization from the bone
marrow into the peripheral circulation of the same cell
populations using granulocyte colony stimulating factor do
not seem to improve functional outcome following MI [83,
84]. In contrast, a recent meta-analysis has suggested a dose
dependent effect when infusing unselected mononuclear
cells [61]. The number of cells used in the many different
trials is very varying from a few millions to more than
thousand millions. Therefore, the discrepancy in outcome
in the clinical studies could be due to differences in amount
of cells used in the treatment.
Mesenchymal stromal cells—a new treatment option?
MSCs are a very interesting cell line due to its multi-
differentiation capacity. However, they are scanty in the
bone marrow and therefore needs a period of culture
expansion to reach a cell number of clinical relevance.
The results from clinical trials in both patients with acute
and chronic ischemic heart disease are promising, but more
trials are needed to evaluate the clinical potential of the
cells. ADSCs from adipose tissue seem to have the same
differentiation capacity as MSCs from bone marrow.
ADSCs are more abundant in and can easily be isolated
from adipose tissue. However, they need to be culture
expanded from the initial isolated adipose derived cells
(ADC) under the same conditions as for MSCs to reach a
clinical interesting level. The regenerative capacity of ADC
and ADSC is presently tested in clinical trials in patients
with acute and chronic ischemic heart disease.
In the PRECISE trial freshly isolated adipose derived
cells (ADC) from the abdominal adipose tissue has been
injected IM in 27 patients with IHF (Avilés et al.,
unpublished data). The study showed a reduction in the
extent of infarct size in the left ventricle and an improve-
ment in maximum oxygen consumption (MVO2) and
patients’ aerobic capacity measured as metabolic equivalents
(METS). The same ADCs were in the APOLLO trial
injected IC in 14 patients with MI (Avilés et al., unpublished
data). There was a trend towards reduction in infarct size.
Which patients to treat
Both the REGENT trial [56] and the REPAIR-AMI trial
[60] have indicated that improvement in LVEF following
cell therapy is mainly restricted to patients with low
baseline LVEF. Therefore, future trials are focusing on
larger infarctions. The timing of the treatment in relation to
the acute MI is varying much between the different studies.
In patients with MI it is suggested to postpone the treatment
approximately one week after the infarction. The period
could potentially be delayed for two to three weeks, since
the spontaneous increase in circulating growth factors and
homing factors reach their maximum two to three weeks
after the infarction [85].
In most trials patients were only followed for a short
period of time (3–6 months) for both efficacy and safety.
There have been indications from the BOOST trial that the
observed short-term improvement is not sustained over a
prolonged period of time in patients with MI [58].
However, Strauer et al. could demonstrate persistent
improvement after IC MNC treatment in patients with heart
failure in a 5-years follow-up period [66].
A normal heart contains 20 million cardiomyocytes per
gram of tissue [86]. Kajstura et al. estimated that the rate of
cardiomyocyte proliferation in the healthy human heart is
approximately 14 cardiomyocytes per million throughout
life. In patients with end-stage ischemic heart disease, the
rate rises more 10-fold to 140 cardiomyocytes per million
[87], yet this degree of turnover appears to be insufficient to
compensate for the massive loss of cardiomyocytes expe-
rienced in chronic heart failure. A patient who has an
infarct that eventually leads to cardiac failure must have
destroyed roughly 25% of the left ventricle. Thus, one
would expect that one billion cardiomyocytes are needed to
improve cardiac function, which is well above the number
of cells that current regenerative strategies can establish. In
clinical regenerative trials with stem cells, the reparative
effects are most likely through other mechanisms than
direct differentiation toward functional tissue, which in-
clude diminishing inflammation, reducing apoptosis, induc-
ing angiogenesis, stimulating paracrine effects or
decreasing fibrosis.
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Perspectives
Regenerative medicine with stem therapy to restore normal
cardiac function in patients with ischemic heart disease is a
new treatment modality, which is explored intensively these
years. Clinical studies on stem cell therapy for cardiac
regeneration in patients with acute and chronic ischemic
heart disease have in some but not all studies shown
significant improvements in ventricular pump function,
ventricular remodeling, myocardial perfusion, exercise
capacity and clinical symptoms, compared to convention-
ally treated control/placebo groups. The mechanisms
behind the potential regenerative capacity of stem cells
could be replacement of the myocardium or blood vessels
by trans-differentiation or more likely an effect of the
cytokines produced by the stem cells on resident cells
within the heart. The different treatment regimes using bone
marrow or adipose tissue derived stem cell solutions have
all been safe. However, there are still many unanswered
questions regarding optimal cell type and number, cell
source and delivery methods. Some of these questions will
be answered in the ongoing or planned larger double-
blinded placebo controlled clinical trials to elucidate
whether stem cell therapy will be a new treatment modality
in patients with ischemic heart disease. When these results
are available, then it will be possible to move forward for a
more individual and personalized stem cell treatment
strategy in patients with ischemic heart disease.
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